ScreenerHero

AURAAura Biosciences Inc. Common Stock

NAS · US · Healthcare · Biotechnology · aurabiosciences.com
7.800USD+0.13%Mkt Cap: 808.90M $P/E: —

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like par…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap808.90M $
Enterprise Value498.54M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-106.19M $
Revenue/Share—
Last Price7.800 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees113
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.83
PEG—
EV/EBITDA-3.64
EV/Revenue—
P/S—
P/B2.55
EPS (TTM)-1.73
EPS (Forward)-2.03
52W Range
4.73064% of range9.535
52W High9.535 USD
52W Low4.730 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-77.56%
ROA-62.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-84.74M $
CapEx (TTM)447.00K $
FCF Margin—
FCF Yield-6.96%
Net Debt-307.25M $
Net Debt/EBITDA2.24
Balance Sheet
Debt/Equity0.13
Current Ratio16.82
Quick Ratio16.65
Book Value/Sh3.047 USD
Cash/Share3.123 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)16.60 USD
Upside (mean)+112.8%
Target Range12.00 USD – 23.00 USD
$12.00+112.8% to mean$23.00
# Analysts5
Ownership
Shares Out.103.70M
Float78.64M
Insiders1.18%
Institutions94.30%
Short Interest
Short Ratio11.7d
Short % Float6.19%
Short % Out.6.15%
Shares Short6.36M
Short (prev mo.)6.93M
Technical
SMA 507.106 (+9.8%)
SMA 2006.486 (+20.3%)
Beta0.40
S&P 52W Chg18.16%
Avg Vol (30d)613.42K
Avg Vol (10d)1.10M
Technical Indicators
RSI (14)59.7
MACD0.2061
MACD Signal0.1822
MACD Hist.+0.0240
BB Upper8.171 USD
BB Middle7.439 USD
BB Lower6.706 USD
BB Width19.71%
ATR (14)0.4367 USD
Vol Ratio (20d)0.71x